Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04741997 · ClinicalTrials.gov registry record · Early Phase 1
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
A Early Phase 1 study of Melanoma Stage IV and Melanoma Stage III, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04741997 is a Early Phase 1 study of Melanoma Stage IV and Melanoma Stage III that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 50 participants, below the 100-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04741997, a Early Phase 1 study of Melanoma Stage IV and Melanoma Stage III, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Encorafenib Pill
- DRUG Binimetinib Pill
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2027-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04741997
The ClinicalTrials.gov registry entry for NCT04741997 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (50% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Melanoma Stage IV appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04741997 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04741997 about?
NCT04741997 is a clinical study titled "Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma". The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy.
What is the current status of trial NCT04741997?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2021-05-24. Estimated completion is 2027-07.
What conditions does trial NCT04741997 study?
This clinical trial studies the following conditions: Melanoma Stage IV, Melanoma Stage III, BRAF V600 Mutation.
What interventions are being tested in trial NCT04741997?
The interventions under investigation include: Nivolumab (DRUG), Encorafenib Pill (DRUG), Binimetinib Pill (DRUG).
Who is sponsoring clinical trial NCT04741997?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04741997 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma Stage IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
RECRUITING · Phase 2
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
RECRUITING · Phase 2
-
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.